Cardiovascular events
We analyzed the risk of cardiovascular events of HIF-PHIs in 17 trials, including 13,492 participants[2, 12, 16, 26-28, 30-39]. No obviously increased RR was indicated in DD patients with Roxadustat (RR: 1.00, 95% CI: 0.88-1.14, p=0.97, I2=0%), Enarodustat (RR: 2.97, 95% CI: 0.12-71.80, p=0.50, I2=0%), Daprodustat (RR: 0.96, 95% CI: 0.85-1.08, p=0.48, I2=0%), Vadadustat (RR: 0.94, 95% CI: 0.83-1.07, p=0.35, I2=0%) and Molidustat (RR: 0.82, 95% CI: 0.38-1.73, p=0.60, I2=0%) compared with the ESAs. The SUCRA rankings were Molidustat (0.70), Vadadustat (0.66), Daprodustat (0.59), Roxadustat (0.42), ESAs (0.40) and Enarodustat (0.24) (Figure 4). The trial of Molidustat and Desidustat were excluded because neither total nor scattered cardiovascular events were reported[40, 41].